The phospholipase A 2 (PLA 2 ) family is a very diverse group of enzymes, all serving in the cleavage of phospholipids, thereby releasing high amounts of arachidonic acid (AA) and lysophospholipids. AA serves as a substrate for prostaglandin production, which is of special importance in pregnancy for the onset of parturition. Novel research demonstrates that PLA 2 action affects the immune response of the mother toward the child and is therefore probably implied in the tolerance of the fetus and prevention of miscarriage. This review presents data on the biochemical and enzymatic properties of PLA 2 during gestation with a special emphasis on its role for the placental function and development of the fetus. We also critically discuss the possible pathophysiological significance of PLA 2 alterations and its possible functional consequences. These alterations are often associated with pregnancy pathologies such as preeclampsia and villitis or pregnancy complications such as obesity and diabetes in the mother as well as preterm onset of labor.
Introduction to the PLA 2 superfamily
The phospholipase A 2 (PLA 2 ) superfamily consists of enzymes of very diverse nature with respect to their cellular localization, dependency on cofactors, and substrate preference. As a consequence of this diversity, PLA 2 enzymes have been implicated in various biochemical processes (Kudo & Murakami 2002 , Quach et al. 2014 . Common to all these enzymes, however, is that all of them catalyze the hydrolysis of an ester bond at the second carbon group (sn-2 position) of a glycerophospholipid releasing a free fatty acid (FFA) and a lysophospholipid. The fatty acid freed from the lipid backbone is in many cases arachidonic acid (AA; C20:4), which is used within the cyclooxygenase (COX) or the lipoxygenase (LOX) pathway to form prostaglandin (PG) and thromboxane or leukotriene respectively. These metabolites are important mediators of inflammation. However, more importantly, eicosanoic lipid mediators generated within the COX pathway are crucial for the coordinated and timely onset of labor. Moreover, PGs are essential to ovulation, fertilization, and implantation, and endocannabinoids are important for synchronizing preimplantation embryo development with uterine receptivity for implantation. Additionally, phospholipases also play a role in the remodeling and the stability of lipid membranes (Robichaud et al. 2015) , therefore affecting placental and fetal development during pregnancy. In the following, an overview of PLA 2 family members will be provided, with special emphasis on those family members that are important in pregnancy, pregnancy pathologies, and (preterm) parturition.
Classification of human PLA 2 family members
Many different aspects are used to subdivide PLA 2 family members into four groups, with the most commonly found classification being that according to Dennis (Schaloske & Dennis 2006) . This system uses cellular localization as well as calcium dependency to distinguish PLA 2 groups. An overview of PLA 2 family members is provided in Table 1 . Important structural features of each PLA 2 group are depicted in Fig. 1 , whereas Fig. 2 summarizes the action of PLA 2 isozymes in maternal and fetal circulation as well as reproductive tissues.
Secretory PLA 2
Secretory PLA 2 s (sPLA 2 s) form the largest group within the calcium-dependent PLA 2 family (Murakami et al. 2011a,b) . They are typically very small enzymes ranging between 14 and 19 kDa, with the exception of PLA 2 -III (55 kDa). Apart from PLA 2 -XII, all group members are closely related and share significant sequence homology. All family members share six absolutely conserved disulfide bonds as well as some additional ones (Kudo & Murakami 2002) , which are specific to enzyme. In close proximity to one another, a histidine-aspartic acid catalytic dyad and a calciumbinding loop are found in all the sPLA 2 s. It is also noteworthy that many sPLA 2 family members tightly R92 C Besenboeck and others bind to heparan sulfate proteoglycans as the cationic cargo of the enzyme. Therefore, rather than being secreted, they are often located in cell membranes within the extracellular matrix (Murakami et al. 1996) . sPLA 2 -IIA acts as a pro-inflammatory enzyme, which is constitutively expressed within various tissues and cells. Both neutrophils and macrophages are able to store the enzyme in granules and secrete it upon activation (Balsinde et al. 1996) . sPLA 2 -IIA is up-regulated by pro-inflammatory cytokines; downregulated by glucocorticoids, transforming growth factor-b, and interleukin 10 (IL10; Kuwata et al. 1998) ; and additionally holds antimicrobial and anticoagulant properties (Mounier et al. 1996 , Qu & Lehrer 1998 .
High levels of plasma sPLA 2 -IIA are associated with pathologies characterized by a high degree of inflammation, such as septic shock (Pruzanski & Vadas 1991) , rheumatoid arthritis (Seilhamer et al. 1998) , atherosclerosis (Webb 2005) , and respiratory distress syndrome (Masuda et al. 2005) , and more importantly during labor (Lappas et al. 2004) . sPLA 2 -V sPLA 2 -V is another important member of the secretory phospholipase group, likely owed to the fact that it can substitute for sPLA 2 -IIA activity. It is highly expressed in myocytes, but also in immune cells such as mast cells, macrophages, and Th2 cells (Balboa et al. 1996) . Similar to sPLA 2 -IIA, it is up-regulated by pro-inflammatory stimuli such as IL1; however, it cannot be downregulated by glucocorticoids (van der Helm et al. 1996 , Thomas et al. 2000 .
In addition to cytokines and hormones, receptors for sPLA 2 s (PLA2R) have been found to provide a regulatory mechanism for sPLA 2 enzymes. PLA2R forms may be produced by the action of metalloproteinases and are highly expressed in the kidney, but also expressed in pancreas, amnion, chorion-decidua, and placenta (Moses et al. 1998) . PLA2R1 binds sPLA 2 groups I, II, V, and X but not III and XII. It is an 180 kDa integral Pancreatic lipase  14  mM  PS, PE, PC  AA, EPA, DHA, OA, LA  IIA  Synovial lipase  14  mM  PS+PE>PC  AA, EPA, DHA, OA, LA  IIC  15  mM  PS, PE, PC  AA, EPA, DHA, OA, LA  IID  14  mM  PS, PE, PC  AA, EPA, DHA, OA, LA  IIE  14  mM  PS, PE, PC  AA, EPA, DHA, OA, LA  IIF  16  mM  PS, PE, PC  AA, EPA, DHA, OA, LA  V  14  mM  PS+PE+PC  AA, EPA, DHA, OA, LA  X  14  mM  PS+PE+PC  AA, EPA, DHA, OA, LA  III  55  mM  PS, PE, PC  AA, EPA, DHA, OA, LA  XII  19  mM  PC>PS+PE  AA, EPA The official numbering system using Latin numbers as well as commonly used trivial names are given. Protein size (kDa), Ca 2+ dependency, and major substrates are indicated. In addition to the mentioned lipases, recently two lysosomal PLA 2 s (aiPLA 2 and LPLA 2 ) as well as an adipose tissue-specific PLA 2 (AdPLA 2 ) have been discovered. PLA 2 isozymes highlighted in bold are those playing a major part in pregnancy and therefore discussed in this review. sPLA 2 , secretory phospholipase A 2 ; cPLA 2 , cytosolic phospholipase A 2 ; iPLA 2 , intracellular, calciumindependent PLA 2 ; PNPLA, patatin-like phospholipase; ATGL, adipocyte triglyceride lipase; NTE, neuropathy target esterase; NRE, neuropathy target-related esterase; PAF-AH, platelet-activating factor-acetyl hydrolase.
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Phospholipase A 2 in pregnancy R93 membrane receptor with a very large extracellular and a very small intracellular domain. Although its precise function remains unclear, binding of sPLA 2 to its receptor participates in both positive and negative regulation of sPLA 2 functions as well as clearance of sPLA 2 . PLA2R1 seems to serve pleiotropic effects apart from fatty acid metabolism, regulate cell senescence, aging, and cancer (Lambeau 1999 , Augert et al. 2013 , and to be the major auto-antigen in nephropathy (Stanescu et al. 2011) .
Cytosolic PLA 2 s
The cytosolic PLA 2 (cPLA 2 ) subfamily consists of three isozymes that are expressed in the cytosol of most cell types ubiquitously and constitutively (Leslie 1997 , Hirabayashi & Shimizu 2000 . This includes cell types of the uterus and trophoblasts of the placenta, which makes cPLA 2 enzymes important in fertility, ovulation, implantation, and placentation (Uozomi et al. 1997 , Song et al. 2002 . The activity of cPLA 2 and sPLA 2 enzymes seems to be interconnected (Murakami et al. 1998) .
Intracellular, calcium-independent PLA 2 s Intracellular, calcium-independent PLA 2 (iPLA 2 ) isozymes are often also referred to as patatin-like phospholipases (PNPLAs). Although there are nine members of human PNPLAs, not all these enzymes have been assigned an abbreviation within the PLA 2 classification system because most PNPLA/iPLA 2 family members do not elicit classical PLA 2 activity. Some PNPLAs/iPLA 2 s also have triglyceride (TG) lipase, lysophospholipase, esterase, or trans-acetylase activity, but no phospholipase activity at all (Murakami et al. 2011a,b) . The most important member of this group is adipose TG lipase (ATGL). ATGL mainly hydrolyzes dietary TG and activates TG stored in lipid droplets and white adipose tissue (Zechner et al. 2009 ). ATGL has also been shown to be expressed in human and rodent placental tissue (Barrett et al. 2014) .
Platelet-activating factor-acetyl hydrolases
The family of platelet-activating factor-acetyl hydrolases (PAF-AH), which degrades pro-inflammatory phospholipids (PAF), consists of two intracellular isoforms (Ib and II) and one secreted isoform (plasma). The plasma and tissue concentration of PAF is determined by a balance between its biosynthesis and degradation (Arai et al. 2002) .
Plasma PAF-AH
The more commonly termed lipoprotein-associated PLA 2 (LpPLA 2 ) is an extracellular enzyme produced and secreted mainly from differentiated macrophages (Tjoelker et al. 1995) . In systemic circulation, this enzyme attaches to LDL (80%) and HDL (20%) particles. LpPLA 2 possesses a unique substrate preference for oxidized phospholipids, chemically resembling PAF, which is the principal substrate of LpPLA 2 . The exact role of the enzyme, pro-or anti-inflammatory, remains enigmatic (Marathe et al. 2014) and might depend on association with either LDL or HDL (Lagos et al. 2009 , Tellis & Tselepis 2009 ). Serum LpPLA 2 levels are elevated in a number of inflammatory conditions (Vickers et al. 2009 ), but also familiar to hypercholesterolemia and diabetes (Serban et al. 2002 , Tsimihodimos et al. 2002 , Silva et al. 2011 . In pregnancy, elevated serum LpPLA 2 levels have been measured in mothers suffering from pregnancy hypertension, preeclampsia (PE), and gestational diabetes mellitus (GDM) -all are pregnancy-associated diseases.
PAF-AH-II
PAF-AH-II is an intracellular enzyme that shares about 41% sequence homology with the plasma form, LpPLA 2
Figure 2
Overview of PLA 2 family members in maternal circulation, uterine layers, placenta, placental membranes, and fetal circulation. Only the most important PLA 2 isozymes and pregnancy pathologies are highlighted in this schematic overview. Factors regulating PLA 2 isozymes, e.g. cytokines, chemokines, and phospholipids (not indicated in the scheme), are present in both maternal and fetal circulation. R94 C Besenboeck and others (Matsuzawa et al. 1997) . It exerts a substrate preference similar to LpPLA 2 but acts intracellularly with not only hydrolase but also trans-acetylase activity. High levels of intracellular PAF-AH-II activity have been detected in placental trophoblast cells, suggesting its possible relationship with labor induction (Gu et al. 2006 ).
PAF-AH-Ib
PAF-AH-Ib is an intracellular, hetero-trimeric enzyme with substrate preference for PAF, but not oxidized phospholipids. The tissue-specific enzyme distinctly reveals the importance in the development of fetal brain and spinal cord; however, apart from that, no further known association with pregnancy has been described so far (Hattori et al. 1994) .
In addition, recently two lysosomal PLA 2 s (aiPLA 2 and LPLA 2 ) as well as an adipose tissue-specific PLA 2 (AdPLA 2 ) have been discovered but are not yet extensively studied (Murakami et al. 2011a,b) .
Serum PLA 2 levels in pregnancy
The best investigated PLA 2 family member in general, but also in pregnancy, is sPLA 2 -IIA (synovial phospholipase). Although the cellular origin of sPLA 2 -IIA seems to be still unknown, in pregnant women, several uterine tissues, the placenta, and fetal membranes express high amounts of sPLA 2 -IIA. This is corroborated by increased activity of PLA 2 during late gestation, which could be likely due to the impact of hormones such as estrogen, which is elevated during pregnancy. Oxytocin is another potential factor that could be contributing to modulating PLA 2 levels. It is the most potent uterotonic agent known so far, and Lefebvre et al. (1992) showed that during gestation, oxytocin mRNA increases at term, supporting the idea that it may act as a local mediator rather than a circulating hormone.
PLA 2 levels in the first trimester
Hayashi et al. (2000) investigated serum sPLA 2 -IIA levels in non-pregnant women during their menstrual cycle, as well as in pregnant women throughout the pregnancy. In non-pregnant women, serum sPLA 2 -IIA levels were lowest in the luteal phase and comparably high in the menstrual and follicular phases. In pregnant women, serum sPLA 2 -IIA levels were about twice as high as in the menstrual and follicular phases; however, this did not reach statistical significance. Also, among the three trimesters, no further changes in serum sPLA 2 -IIA levels were observed. There was also no significant difference for circulating PLA 2 -IIA levels between maternal and fetal serum; however, interestingly, serum PLA 2 -IIA concentrations were significantly higher in postpartum women than in normal pregnant women. These results suggest that a regulatory mechanism of PLA 2 -IIA may exist during the normal menstrual cycle and at puerperium. However, this study contradicted the work of Pulkinnen et al. (1993) that clearly showed low levels of sPLA 2 -IIA during the first trimester, likely to allow for proper implantation, and that sPLA 2 is in turn induced significantly during labor, to allow parturition. In this study, not only sPLA 2 -IIA concentration but also total PLA 2 activity was assessed. Serum concentration and activity correlated significantly, which can be explained by sPLA 2 -IIA, making up for about 80% of total sPLA 2 activity.
PLA 2 levels at term and in preterm labor
The induction of parturition is dependent on three rate-limiting steps: first, the release of AA, which is catalyzed by the action of both secretory and cPLA 2 family members. Secondly, the released AA converts to lipid mediators by COXs (COX1 and COX2), and in the last step, specific PG synthases produce PGs, which is needed for the onset of labor from these precursors. Despite the progress in this field, the lack of identification of the mechanisms of human parturition has limited the specific and effective diagnosis and treatment of preterm labor and subsequent birth. Therefore, sPLA 2 -IIA was also extensively investigated in the serum of preterm labored women. A study on 38 women delivering preterm showed that their serum sPLA 2 -IIA concentration and activity were significantly higher than those in a control group delivering at term. Within the preterm group, 19 women were suffering from chorioamnionitis, an infection associated with severe inflammation. Within this subgroup, sPLA 2 -IIA concentration and activity were even higher compared with the general preterm group. Also inflammatory markers such as CRP, IL8, and IL6 levels were significantly elevated in the sera of women with amnionitis compared with those delivering preterm without infection or the control group. In total, these observations suggest that sPLA 2 -IIA concentration may be a useful indicator for preterm labor, and phospholipid metabolism is certainly activated both in preterm labor and in apparent inflammatory diseases (Koyama et al. 2000) .
PLA 2 levels in PE and GDM
Increased serum levels of sPLA 2 -IIA have been reported in pregnant women suffering from both mild and severe PE (Pulkkinen et al. 1993 , Lim et al. 1995 ; however, other studies contradicted these findings (Tempfer et al. 2001) . Conclusions drawn from studies on PE have to be interpreted carefully as children from PE pregnancies are often delivered pre-maturely and control groups would have to be matched for gestational age. Appropriate control groups were not indicated in all the mentioned www.reproduction-online.org
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In the last few years, LpPLA 2 (plasma PAF-AH) has emerged as a biomarker for cardiovascular risk (Castro FariaNeto et al. 2004 ) and has extensively been studied in atherosclerosis, hyperlipidemia, diabetes, and metabolic syndrome (MetS). Throughout the course of pregnancy, mothers adapt to a lot of metabolic challenges such as insulin resistance, hyperlipidemia, and possibly hypertension. Some pregnancies are therefore affected by conditions such as GDM, cholestasis, or hypertension, which are considered transient and disappear after delivery. Nevertheless, there is an increased risk for cardiovascular disease in these mothers later in their lives. Three recent studies investigated LpPLA 2 levels in postpartum women. Derbent et al. investigated LpPLA 2 levels in women with a history of GDM with respect to their future risk of developing MetS. This is the first study which found that women -who had delivered up to 5 years before the study was conducted -still presented with significantly lower HDL levels but higher insulin resistance index, BMI, and most importantly higher serum LpPLA 2 levels compared with controls (Derbent et al. 2011) . Within the case group, 50% of women showed signs of MetS and 25% were diagnosed with type 2 diabetes mellitus (T2DM). Another study investigating LpPLA 2 levels in women with a history of GDM showed that LpPLA 2 levels in maternal serum remained significantly higher compared with control women for up to 2 years after delivery. In this study, 10% of women who had GDM later developed T2DM, 20% had signs of MetS, and 5% became hypertensive (Mai et al. 2014) . Furthermore, Zhou et al. found that LpPLA 2 levels as well as LDL-C, TG, and blood pressure were higher in women with a history of PE than in controls. LpPLA 2 mass was correlated with the development of postpartum hypertension (systolic blood pressure) as well as LDL-C levels (Zhou et al. 2014) .
Another study that investigated LpPLA 2 in pregnancy hypertension was conducted prospectively in 51 pregnant women, whose LpPLA 2 levels were measured in the first, second, and third trimester of pregnancy (Okumura et al. 1999) . Of these, ten women developed pregnancyinduced hypertension (PIH) later in the third trimester. The general observation among the study population was that LpPLA 2 levels were higher in the first than in the second and third trimesters. However, this was not true for all women and some still had increasing LpPLA 2 levels over the second and third trimesters. Of the total women, 43% who had high levels of LpPLA 2 in the second trimester also developed PIH, whereas only 8% of women who had low levels of LpPLA 2 in the second trimester developed PIH. The authors therefore suggested LpPLA 2 levels along the course of pregnancy as one potential risk marker for PIH.
PLA 2 in the human placenta
AA mobilization by PLA 2 and subsequent PG synthesis is thought to be a pivotal event in the onset and/or maintenance of human labor. Although PLA 2 isozymes have been extensively studied within uterine tissues, different placental cell types, and fetal membranes, their role in homeostasis and pathophysiology during pregnancy has not been clearly established. The placenta as the connective organ between mother and fetus acts as the separating barrier between the maternal and fetal circulations and ensures nutrient and oxygen supply from the mother to the growing infant. In this context, PLA 2 action within the placenta is not only important in parturition (Lappas et al. 2004 ) but also for catabolism and transport of TG from the mother to the fetus across the placenta (Freed et al. 1997) .
So far, three PLA 2 isozymes have been shown to be especially important for placental AA release and onset of parturition: sPLA 2 -IIA, sPLA 2 -V, and cPLA 2 -IV, although the mRNA expression levels of these enzymes within the tissue appears to be diverse. sPLA 2 -IIA expression in placental tissue and chorion-decidua was the highest, but undetectable in amnion. sPLA 2 -V mRNA was highly expressed in the placenta and amnion, but undetectable in decidual tissue. cPLA 2 -IV mRNA was expressed in all the three tissue types at similar levels (Johansen et al. 2000) . A study focusing on sPLA 2 -IIA and cPLA 2 -IV in the human myometrium (Slater et al. 2014) , which is the actual contractile layer within the uterine wall, investigated PLA 2 function and its association with labor and onset at term and preterm deliveries. In this study, myometrial samples were collected from four different groups: a term/no labor, term/in labor, preterm/no labor, and a preterm/in labor group. Both in the preterm and in the term groups, spontaneous onset of labor significantly induced sPLA 2 -IIA expression in the myometrium, whereas cPLA 2 -IV levels remained constant. Therefore, one can speculate that sPLA 2 -IIA plays a more important role in inducing myometrial contractions and labor onset than cPLA 2 -IV.
Placental PLA 2 in term and preterm labor sPLA 2 -IIA and its role in preterm labor was also investigated by Lappas et al. (2001) using preterm and term groups with subgroups being in labor or without previous labor. Decidua, amnion, and placenta samples were assayed for both sPLA 2 -IIA concentration and total PLA 2 activity. The main outcome of this study was a significant increase in sPLA 2 -IIA in amnion and decidua in the preterm compared with the term group. Furthermore, increased levels of sPLA 2 -IIA in amnion in the preterm group were associated with premature rupture of membranes. Interestingly, although infection is often associated with preterm labor, in a subset of women in this study, amnionitis was not characterized by increased levels of sPLA 2 -IIA in decidua, amnion, or placenta compared with R96 C Besenboeck and others controls. A similarly designed study, however, did not find any significant changes in sPLA 2 -IIA neither between preterm and term groups nor between labor and non-labor groups (Munns et al. 1999) . Mosher et al. (2014) investigated another PLA 2 family member, sPLA 2 -IID, in uterine tissue. Also this study compared groups at term with and without labor. sPLA 2 -IID mRNA was shown to be expressed in a very low amount in human myometrium, placenta, and amnion, but by far highest in decidua. mRNA levels are related to protein levels, and interestingly, sPLA 2 -IID mRNA and protein was lower in the labor group. The authors suggested that sPLA 2 -IID may not be important in labor onset but serves an important role in placental immune function and tolerance of the fetus as sPLA 2 -IID has been shown to be an effector for regulatory T-cells (Tregs). Within the decidual layer, Tregs have been shown to be important for proper implantation without rejecting the fetus (Jin et al. 2009 ).
M-type receptor for sPLA 2 s (PLA2R1) has been detected in human placenta (Moses et al. 1998 ) and could represent an additional mechanism regulating sPLA 2 activity within this tissue. PLA2R1 was found to be expressed in chorion-decidua and placental tissue, but not in the amnion. Levels were generally higher in chorion-decidua than in placenta; however, placental expression increased with labor onset.
Placental PLA 2 in pregnancy-related pathologies
The only iPLA 2 member shown to play a role in placental tissue so far is iPLA 2 ζ, more commonly known as ATGL (PNPLA2). Barrett et al. (2014) showed the presence of ATGL in placental tissue for the first time. Immune histochemistry showed the presence of ATGL in placental stromal cells (e.g., Hofbauer cells (HBCs)), syncytiotrophoblast (SCT), and endothelial layer of placental vessels. ATGL (PNPLA2) mRNA, as well as mRNA of its co-activator CGI-58, were up-regulated in GDM placentae. However, this did not translate to enhanced ATGL protein abundancy in GDM placentae. Nevertheless, increased ATGL and CGI-58 could point toward increased lipolysis in GDM placentae. If so, fetuses would receive more TG, which explains the higher fetal fat mass accretion in late pregnancy. This may lead to macrosomia, which is frequently observed in neonates born from diabetic pregnancies (Herrera & Ortega-Senovilla 2010 , Lawlor et al. 2010 .
Also the cytosolic PAF-AH isoforms I and II have been shown to be expressed in pregnant and non-pregnant myometrium (Yasuda & Okumura 2001) . PAF-AH-II is additionally expressed in placental trophoblast cells. A study on PE placentae showed that both the levels of PAF, a potent mediator of inflammation, and trophoblast PAF-AH-II, which is able to degrade PAF, were higher compared with controls (Gu et al. 2006) . Induction of PAF-AH-II was suggested to be a compensatory mechanism to clear PAF and therefore to decrease the inflammatory component of PE.
Glucose intolerance and alterations in lipid metabolism are common features of pregnancy. Newborns of diabetic or obese mothers are often considerably bigger and have higher amounts of body fat than children born to normoglycemic or lean mothers (Durnwald et al. 2004) . This reflects that the metabolic status of the mother affects the offspring's outcome already in utero. As the action of PLA 2 s also gives rise to pro-inflammatory lipid mediators, they likely represent a link between inflammation and lipid metabolism. To the best of our knowledge, the only study investigating PLA 2 family members in the placenta focusing on lipid catabolism between the mother and the fetus was conducted by Varastehpour et al. (2006) . They investigated PLA 2 mRNA levels in the placenta of normal and obese newborns and found that sPLA 2 -IIA, sPLA 2 -V, sPLA 2 -VI, and LpPLA 2 mRNA was increased up to three-fold. Also, tumor necrosis factor alpha (TNFα) and leptin mRNA were increased in obese placentae. In vitro, they investigated the effect of TNFα and leptin on sPLA 2 -IIA and sPLA 2 -V and found that the expression of these PLA 2 isozymes was induced. They concluded that increased sPLA 2 action in the placenta of obese neonates may result in even more FFAs available for fetal adipogenesis but also for generation of pro-inflammatory mediators. For a better overview, all studies on PLA 2 in the placenta and their principal results are summarized in Table 2 .
PLA 2 expression in placental cell types
Using gene expression analysis, our research group compared the mRNA levels of various PLA 2 family members in four distinct primary cell types of the human placenta, arterial endothelial cells (AEC), venous endothelial cells (VEC), cytotrophoblasts (CT), and SCT (data analyzed from Cvitic et al. (2013) ; Table 3 ). Comparing the mean expression intensity, PLA2G15 (encoding a lysosomal PLA 2 ) was mostly expressed in AEC and VEC, PLA2G16 (encoding an AdPLA 2 ) in CT, and PLA2G7 (encoding LpPLA 2 ) in SCT. M-type PLA 2 receptor, PLA2R1, was uniformly expressed in all placental cell types. Considering fold-change values, only PLA2G4F (encoding PLA 2 -IV-F, a cPLA 2 ) showed differential expression between AEC and VEC with a 1.82-fold, whereas expression of PLA 2 members in CT and SCT was similar (Table 3) . On contrary, when comparing the expression of PLA 2 members between placental endothelium (combined AEC and VEC expression intensities) and trophoblast (combined CT and SCT expression intensities), most members showed differential expression with an average of 1.71-fold. As the expression of PLA2R1 did not differ between endothelium and trophoblast ( Phospholipase A 2 in pregnancy R97 PLA 2 s are not regulated by the respective receptor in these two placental compartments.
PLA 2 in neonates
Although PLA 2 family members are well investigated in maternal circulation and even more comprehensively in placentae of different hosts, uterine tissue, and fetal membranes, very little is known about PLA 2 levels, activity, and function in the neonatal circulation. Pulkinnen et al. investigated sPLA 2 -IB and -II (pancreatic and synovial phospholipase) levels in umbilical cord blood and found that high levels of sPLA 2 -IB in cord blood were reflected by poor Apgar scores in these neonates. Moreover, pregnancy-induced hypertensive diseases increased by four-to ten-fold the concentration of synovial-type PLA 2 ; in eight out of 14 cases, the enzyme was increased if the fetus was to be delivered prematurely (Pulkkinen et al. 1990 ). However, apart from Apgar score and premature delivery, no other parameters of neonatal distress or inflammatory markers were investigated.
Neonates suffering from meconium aspiration syndrome (MAS) develop respiratory distress. On the one hand, this is caused by sPLA 2 -IB present in meconium itself, which is responsible for the degradation of surfactant and therefore harmful to the neonate's lung development. On the other hand, investigation of pulmonary lavage fluids showed that local production of sPLA 2 -IIA is also contributing to inflammation in MAS (De Luca et al. 2011) .
Additionally, sPLA 2 -IIA levels are well established in the serum of newborns suffering from sepsis, which is a common phenomenon in preterm infants. In a study on newborns admitted to ICU, 24 children with proven sepsis, 77 children with suspected infection, and 55 proven healthy children were investigated for their sPLA 2 -IIA activity. Enzyme activity was highest in the septic children and was also significantly elevated 
sPLA 2 -IIA and sPLA 2 -V; cPLA 2 -IV X X X All three expressed in placenta; amnion cPLA 2 -IV and sPLA 2 -V; chorion sPLA 2 -IIA and cPLA 2 -IV RNA RT-qPCR Johansen et al.
sPLA 2 -IIA and cPLA 2 -IV X X X High amounts of sPLA2-IIA in placenta, high levels of cPLA 2 in amnion 
The expression of PLA 2 isozymes in the placenta and fetal membranes is marked with an X. For better understanding of different results from different studies, sample types and detection techniques used are indicated. RT-qPCR, RT-quantitative real-time PCR; WB, western blot; NB, northern blot; IHC, immunohistochemistry; NI, not investigated.
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in the 'suspected infection' group compared with controls (Schrama et al. 2008) . sPLA 2 activity correlated positively with other markers of inflammation, such as CRP and IL6 levels as well as leukocyte count. Moreover, sPLA 2 -IIA levels were especially high in children experiencing respiratory distress syndrome in addition to sepsis. The authors suggested that this is not only due to high sPLA 2 in serum but also locally high levels of sPLA 2 in neonatal lungs, causing hydrolysis of lung surfactant phospholipids. In adults, sPLA 2 -IIA is already a valid marker of sepsis. A study investigating LpPLA 2 (plasma PAF-AH) activity and distribution among LDL and HDL particles within both maternal serum and neonatal cord blood in PE pregnancies showed that there was no significant alteration in LpPLA 2 activity and distribution in maternal blood caused by PE (Fan et al. 2012) . However, in offsprings born to PE pregnancies, LDL levels were significantly higher than in control neonates. Also LpPLA 2 activity was higher in cord blood in the PE group and activity was elevated in LDL particles compared with controls. In summary, this study showed that the neonates from women with severe PE have higher plasma PAF-AH activities, higher ratio of LDL-PAF-AH to HDL-PAF-AH activities, and higher TG:HDL-C ratio than the neonates from women with normal pregnancies. Results suggest that the neonates of the patients might present a chronic inflammation Values represent mean mRNA expression intensities from endothelium (n = 18) and trophoblast (n = 20) measured by Affymetrix GeneChip Human 1.0 ST arrays. Expression intensities range from 1 to 13. Data were used from Cvitic et al. (2013) . FC, fold-change was calculated as the ratio of mean expression for endothelium vs trophoblast. Values represent mean mRNA expression intensities from AEC (n = 9), VEC (n = 9), CT (n = 10), and SCT (n = 10) measured by Affymetrix GeneChip Human 1.0 ST arrays. Expression intensities range from 1 to 13. Data were used from Cvitic et al. (2013) . FC, fold-change was calculated as the ratio of mean expression for AEC vs VEC and CT vs SCT respectively. AEC, arterial endothelial cells; VEC, venous endothelial cells; CT, cytotrophoblast; SCT, syncytiotrophoblast.
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Conclusion
In general, most pregnancy pathologies are characterized by similar metabolic changes such as elevation of certain cytokines, derailed lipid metabolism, insulin resistance, or infiltration of immune cells into the placenta. Insulin resistance is a necessary metabolic alteration in pregnancy to ensure energy supply of the fetus and to maintain a glucose gradient across the placenta. In GDM, insulin resistance is augmented, and it is also often observed in obese pregnant women as well as women suffering from PE (Rademacher et al. 2007 ). These three conditions have also been characterized by poor maternal lipid profiles, with high TG, high LDL-C, smaller proatherogenic LDL particles, and low HDL-C levels in many studies (Derbent et al. 2011 , Fan et al. 2012 , Mai et al. 2014 . Also, in GDM, obesity, and PE, elevated levels of certain pro-inflammatory cytokines have been reported, e.g. TNFα, IL1b, IL2, and IL6. However, anti-inflammatory IL10 was shown to be down-regulated in these conditions (Gomes et al. 2013 , Raghupathy 2013 , Katzman 2015 . TNFα, IL1, IL6, and IL10 are able to regulate sPLA 2 -IIA and sPLA 2 -V (van der Helm et al. 1996 , Kuwata et al. 1998 . Enhanced activity of these secretory enzymes could contribute to some of the observed symptoms of these conditions: e.g. preterm labor in PE or macrosomia of the fetus by enhanced lipid catabolism in GDM and obesity.
Inflammation and presence of pro-inflammatory cytokines also play an important role in other pregnancy conditions, e.g., chorioamnionitis (an infectious disease of the placenta) and villitis of unknown etiology (VUE, inflammation of the placenta without a detectable infectious agent). Both conditions have been characterized by massive infiltration of placental tissue with T-lymphocytes, macrophages, and also Tregs; Tamblyn et al. 2013 , Faas et al. 2014 . Moreover, an accumulation of placental macrophages (so-called HBCs) has also been reported in GDM and PE pregnancies (Evsen et al. 2013 , Yu et al. 2013 . These macrophages, especially if exposed to pro-inflammatory mediators, enhance the secretion of sPLA 2 s and may therefore cause alterations in PLA 2 activity and changes in lipid metabolism within placental tissue.
PLA 2 s seem to be of tremendous importance throughout various stages of pregnancy as well as in a number of common pregnancy pathologies (as summarized in Table 5 ). Modulation of PLA 2 activity could therefore be a strategy to treat preterm labor onset, GDM (and/or obesity), PE, or placental inflammation. However, treatment opportunities so far are limited: fine-tuned modulation of only certain PLA 2 s would be necessary; however, most inhibitors of PLA 2 activity act rather unspecific on various PLA 2 isozymes (Yedgar et al. 2006 , Garcia-Garcia et al. 2009 ). For instance, inhibitors of sPLA 2 -IIA often also inhibit the closely related enzymes sPLA 2 -V and sPLA 2 -X. Therefore, so far it is more common to reduce PG and leukotriene production in certain inflammatory conditions, e.g. Zhu et al. 2011) . These techniques could also be used in order to overcome the placental barrier, which can be passed by nanoparticles (Grafmüller et al. 2013 , Lopalco et al. 2015 . Nevertheless, in order to develop better treatment strategies, deeper understanding of the relationships between inflammation and lipases and lipid metabolism in the placenta, but also maternal and fetal circulation, is still needed. Future studies will hopefully help in gaining this knowledge and improve health care for mother and child.
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